Abstract
The spike deletion H69-V70 (ΔH69/ΔV70) has been recently detected in a SARS-CoV-2 variant under investigation in England (VUI 202012/01) as well as in cluter-5 variant detected both in minks and humans in Denmark. Herein we report the implementation of a two-step strategy enabling to detect SARS-CoV-2 variants carrying H69-V70 deletion. We found that this deletion resulted in a false negative result for the spike target of a three-target RT-PCR assay (TaqPath kit). From August 3rd to December 20th, 59/9,266 (0.6%) of positive tests displayed a S negative profile (negative for S target and positive for N & ORF1ab targets). Among the 59 samples without detection of the S target, 36 were available for whole genome sequencing (WGS). The most frequent S mutations co-occurring with ΔH69/ΔV70 were S477N & D614G (21/36 samples). The co-occurrence of N439K and D614G mutations was found in 10/36 samples. The complete combination of S mutations detected in VUI 202012/01 or in cluster-5 variant was not found. The data presented herein emphasize that the TaqPath RT-PCR assay enables a rapid, large-scale screening of ΔH69/ΔV70 variants. Samples with S negative profiles should be further addressed to national referral laboratories for SARS-CoV-2 WGS. This 2-step strategy is currently being reinforced in France as national diagnostic platforms have mainly implemented the TaqPath RT-PCR kit.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
Samples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78 17 on 06/01/1978 and Decret 2019 536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was presented by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N 41).
Funding Statement
None
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics statement Samples used in this study were collected as part of an approved ongoing surveillance conducted by the national reference centre for respiratory viruses in Lyon, France (WHO reference laboratory providing confirmatory testing for COVID-19). The investigations were carried out in accordance with the General Data Protection Regulation (Regulation (EU) 2016/679 and Directive 95/46/EC) and the French data protection law (Law 78 17 on 06/01/1978 and Decret 2019 536 on 29/05/2019). Samples were collected for regular clinical management during hospital stay, with no additional samples for the purpose of this study. Patients were informed of the research and their non-objection approval was confirmed. This study was approved by the ethics committee of the Hospices Civils de Lyon (HCL), Lyon, France and registered on the HCL database of RIPHN studies (AGORA N 41).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
SARS-CoV-2 genomes sequenced in this study were deposited in the GISAID database (EPI_ISL_582110, EPI_ISL_582111, EPI_ISL_582112, EPI_ISL_582113, EPI_ISL_582114, EPI_ISL_582115, EPI_ISL_582116, EPI_ISL_582117, EPI_ISL_582118, EPI_ISL_582119, EPI_ISL_582120, EPI_ISL_582508, EPI_ISL_623098, EPI_ISL_623099, EPI_ISL_623100, EPI_ISL_623101, EPI_ISL_623102)
